Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04969315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

StatusRecruiting
PhasePhase 1/2
Started2023-06-23
View on ClinicalTrials.gov ↗
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 2. To determine the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 3. To evaluate safety of combination therapy (TT-10 + TT-4 Diacid).

Amendment history 3 changes detected by DataLookout

2026-09-16
Enrollment reduced: 90 → 35 participants
2026-09-16
Primary completion pushed: 2026-06-01 → 2028-12-01
2026-09-16
Completion pushed: 2027-12-31 → 2029-03-01
Trial Details
NCT Number NCT04969315
Lead Sponsor Portage Biotech
Conditions Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Enrollment 35 participants
Start Date 2023-06-23
Primary Completion 2028-12-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-15